Accedi ai contenuti
Registrati »
Accedi ai contenuti
Registrati »

Introduction: Student pharmacists contribute meaningfully to patient care during Advanced Practice Pharmacy Experiences (APPEs) in varied settings. We aimed to characterize and evaluate the impact of student participation in hematology-oncology (hem-onc) APPEs on the practice site, and on student professionalization. Methods: For students completing hem-onc APPEs during 2016–2019, rotation activities and

Oncology Pharmacy Practice 2022;28(1):109-118. /  Yacobucci MJ, Lombardi CL, Briceland LL.

Background: Debate over the viability of the current commercial research and development (R&D) model is ongoing. A controversial theme is the cost of bringing a new molecular entity (NME) to market. Objective: Our aim was to evaluate the range and suitability of published R&D cost estimates as to the degree to

PharmacoEconomics 2021; 39: 1243–1269. /  Schlander M, Hernandez-Villafuerte K, Cheng, CY. et al.

To comprehensively classify interventions performed by ICU clinical pharmacists and quantify cost avoidance generated through their accepted interventions. Design: A multicenter, prospective, observational study was performed between August 2018 and January 2019. Setting: Community hospitals and academic medical centers in the United States. Participants: ICU clinical pharmacists. Interventions: Recommendations classified into one of 38 intervention categories (divided into

Crit Care Explor 2021;3(12):e0594. /  Rech MA, Gurnani PK, Peppard WJ, et al.

Importance: There is clinical equipoise for COVID-19 convalescent plasma (CCP) use in patients hospitalized with COVID-19. Objective: To determine the safety and efficacy of CCP compared with placebo in hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen. Design, setting, and participants: CONTAIN COVID-19, a randomized, double-blind, placebo-controlled trial of CCP in hospitalized adults with COVID-19,

JAMA Intern Med 2021 Dec 13 Epub ahead of print. PMID: 34901997. /  Ortigoza MB, Yoon H, Goldfeld KS, et al.

Vaccines against SARS-CoV-2 have shown remarkable efficacy and thus constitute an important preventive option against COVID-19, especially in fragile patients. We aimed to systematically analyse the outcomes of patients with haematological malignancies who received vaccination and to identify specific groups with differences in outcomes. The primary end point was antibody

Haematologica 2021 Dec 16. Online ahead of print. /  Gagelmann N, Passamonti F, Wolschke C,

Background: Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we investigated the reactogenicity and immunogenicity of seven different COVID-19 vaccines as a third dose after two doses of ChAdOx1 nCov-19

Lancet 2021; 398 (10318): 2207-2306. /  Munro AP, et al.

Emerging SARS-CoV-2 variants, especially those of concern, may have an impact on the virus's transmissibility and pathogenicity, as well as diagnostic equipment performance and vaccine effectiveness. Even though the SARS-CoV-2 Delta variant (B.1.617.2) emerged during India's second wave of infections, Delta variants have grown dominant internationally and are still evolving.

J Med Virol 2021 Dec 15. Online ahead of print. /  Kumar S, Thambiraja TS, Karuppanan K, et al.

Purpose: Drug protocols in intensive care units may require the concomitant administration of many drugs as patients’ venous accesses are often limited. A major challenge for clinicians is to limit the risk of simultaneously infusing incompatible drugs. Incompatibilities can lead to the formation of particles and inactivation of drugs, whose

Eur J Clin Pharmacol 2021; 77: 1309–1321. /  Négrier, L., Martin Mena, A., Lebuffe, G. et al.

Background: Tisagenlecleucel is an autologous CD19-directed T-cell immunotherapy that provides high rates of durable response, with a manageable safety profile, in adult patients with R/R diffuse large B-cell lymphoma (DLBCL). An overall response (OR) rate of 53% and progression-free survival (PFS) rate of ~35% at 12 months were observed in

ASH Meeting 2021; abstract #429. /  Landsburg DJ, et al.

Background: Although oral anticancer medications (OAM) provide opportunity for treatment at home, challenges include prescription filling, monitoring side effects, safe handling, and adherence. We assessed understanding of and adherence to OAM in vulnerable patients. Methods: This 2018 pilot study defined vulnerable patients based on Chinese language, older age (≥65 years), and subsidized

Rodday AM, Hackenyos D, Masood R, et al. /  Rodday AM, Hackenyos D, Masood R, et al.